NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/06/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,225.97 mln
Float82.52 mln
Earnings Date08/05/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
71.37
Highly suspicious
1-Year Forecast
51.40
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-29.28
Deeply negative
Business Description
NewAmsterdam Pharma is a Netherlands-based drug development company focused on treating heart and metabolic conditions. Its lead drug, Obicetrapib, is a low-dose oral pill designed to reduce harmful cholesterol levels, currently being tested in multiple clinical trials both on its own and alongside another cholesterol-lowering agent. The company is also exploring whether Obicetrapib may offer benefits for patients with Alzheimer's disease.
